Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01763827 · ClinicalTrials.gov registry record · Phase 3
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 615
- Enrollment target
NCT01763827: Completed Phase 3 study, sponsored by Amgen.
NCT01763827 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 615 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01763827, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 615 participants
- Enrollment target
Study Summary
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less.
Interventions
- DRUG Ezetimibe
- BIOLOGICAL Evolocumab
- OTHER Placebo to Ezetimibe
- BIOLOGICAL Placebo to Evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 615 participants |
| Start Date | 2013-01-21 |
| Est. Completion | 2013-10-29 |
| Phase | Phase 3 |
What the finished NCT01763827 record still lists
NCT01763827 is an interventional study that assigns participants to a tested intervention. The registered 615 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 4 interventions - of which Ezetimibe is the first listed.
NCT01763827 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01763827 about?
NCT01763827 is a clinical study titled "Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2". The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk ...
What is the current status of trial NCT01763827?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 615 participants. The study started on 2013-01-21. Estimated completion is 2013-10-29.
What interventions are being tested in trial NCT01763827?
The interventions under investigation include: Ezetimibe (DRUG), Evolocumab (BIOLOGICAL), Placebo to Ezetimibe (OTHER), Placebo to Evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01763827?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01763827's enrollment target sits among peer trials
615 593rd of 2000 higher than 1,408 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06593652 · 615 participants · NA
Evaluating Caregiver Involvement in Primary Care-Based Brief Interventions for Adolescent Alcohol Use Problems
- NCT04813185 · 616 participants · NA
Preventing Retaliatory Gun Violence in Violently Injured Adults
- NCT06105957 · 616 participants · NA
Optimal Digital Weight Loss Treatment for Rural Individuals
- NCT06162221 · 616 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI